{"id":"W3007877035","doi":"10.1016/j.ygyno.2020.01.037","title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"ImmunoGen","keywords":"Medicine; Bevacizumab; Ovarian cancer; Adverse effect; Internal medicine; Gastroenterology; Combination therapy; Oncology; Pharmacology; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009810947,0.0003764808,0.001318606,0.0003693628,0.00009191405,0.00001942478,0.0002895003,0.0002503358,0.0006162657],"category_scores_gemma":[0.0007343756,0.0002896686,0.00004310335,0.001320294,0.0002276159,0.0001610771,0.0001366708,0.0009035625,0.00001540093],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001288814,"about_ca_system_score_gemma":0.00127529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001958635,"about_ca_topic_score_gemma":0.00771715,"domain_scores_codex":[0.9958949,0.0007471783,0.001027134,0.0008395578,0.000713551,0.0007776493],"domain_scores_gemma":[0.9978526,0.0005237007,0.0005268204,0.0003294428,0.0005046332,0.0002628131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03514999,0.02172833,0.9068547,0.0004126655,0.0002948299,0.000994665,0.009606511,0.0002399032,0.006972606,0.00005748282,0.0007617205,0.01692657],"study_design_scores_gemma":[0.189955,0.1351273,0.6640524,0.0004109266,0.0002036177,0.000005538083,0.004566277,0.001843519,0.0009847786,0.00004835307,0.002193795,0.0006084651],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918165,0.0001541606,0.0000261553,0.003061546,0.0001664116,0.004058216,0.00007830602,0.00006514177,0.0005735548],"genre_scores_gemma":[0.9975169,0.00004989591,0.001255486,0.0005193928,0.0000485773,0.0003293815,0.000177715,0.00005880472,0.00004389925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2428023,"threshold_uncertainty_score":0.9999555,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02997953848334814,"score_gpt":0.3614315190257628,"score_spread":0.3314519805424146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}